Most Read Articles
Pearl Toh, 15 Dec 2020
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.

Product Highlight - Ferinject

09 Dec 2020

Presentation: Each 10 mL vial contains 500 mg of iron as ferric carboxymaltose.

Indication: Ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. The diagnosis of iron deficiency must be based on laboratory tests.

Dosage & Administration: The individual iron need for repletion using Ferinject is determined based on the patient’s body weight and haemoglobin (Hb) level.

Hb Patient body weight
g/dl mmol/L below 35 kg 35 kg to <70 kg 70 kg and above
<10 <6.2 500 mg 1,500 mg 2,000 mg
10 to <14 6.2 to <8.7 500 mg 1,000 mg 1,500 mg
≥14 ≥8.7 500 mg 500 mg 500 mg

The maximum recommended cumulative dose of Ferinject is 1,000 mg of iron (20 mL Ferinject) per week.



Reference:
Ferinject Product information: FDA Thailand approval, April 2020

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 15 Dec 2020
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.